MedTrace Logo

Implementing PrEP for Women Who Inject Drugs

NCT05360849 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-04-21

No results posted yet for this study

Summary

Women who inject drugs are among the most vulnerable to acquiring HIV, but very few women who inject drugs are prescribed pre-exposure prophylaxis (PrEP) for HIV prevention largely due to barriers within our healthcare system. This research will consider the perspectives of women who inject drugs, healthcare providers, and clinic leadership to improve the way primary care and reproductive health clinics deliver PrEP to women who inject drugs, thereby reducing new HIV infections in this population.

Conditions

  • HIV
  • Intravenous Substance Abuse
  • Women's Health
  • Organization and Administration
  • Primary Prevention
  • Implementation Science

Interventions

BEHAVIORAL

Practice Facilitation

Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs

Sponsors & Collaborators

Principal Investigators

  • Laura Starbird, PhD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-22
Primary Completion
2027-03-24
Completion
2027-03-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360849 on ClinicalTrials.gov